Document is current
Any future updates will be listed below
-
Authors
Katsoulis, Orestis
Toussaint, Marie
Jackson, Millie M.
Mallia, Patrick
Footitt, Joseph
Mincham, Kyle T.
Meyer, Garance F. M.
Kebadze, Tata
Gilmour, Amy
Long, Merete
Aswani, Andrew D.
Snelgrove, Robert J.
Johnston, Sebastian L. http://orcid.org/0000-0003-3009-9200
Chalmers, James D.
Singanayagam, Aran http://orcid.org/0000-0001-9849-0033
-
Funding
Funding for this research was provided by:
RCUK | Medical Research Council (MR/V000098/1)
- License Information
-
More Information
Article History
Received: 12 December 2023
Accepted: 3 July 2024
First Online: 9 July 2024
Competing interests
: S.L.J. has personally received consultancy fees from AstraZeneca, Bioforce, Enanta and GlaxoSmithKline. S.L.J. is an inventor on patents on the use of inhaled interferons for treatment of exacerbations of airway diseases and on rhinovirus vaccines. S.L.J. is Director and shareholder of Virtus Respiratory Research Ltd. JDC has received research grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Grifols, Novartis, Insmed and Trudell; and received consultancy or speaker fees from Antabio, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Insmed, Janssen, Novartis, Pfizer, Trudell and Zambo. A.S. has received honoraria for speaking from AstraZeneca. A.D.A. is Chief Medical Officer at Santersus AG. The remaining authors declare no competing interests.
